van der Feltz-Cornelis C M, Aldenkamp A P
Department of Psychopathology, Netherlands Epilepsy Centre SEIN, Heemstede, and Neurology Department, University of Maastricht, The Netherlands.
Epilepsy Behav. 2006 May;8(3):659-62. doi: 10.1016/j.yebeh.2006.01.015. Epub 2006 Feb 28.
The purpose of this study was to evaluate the effectiveness and safety of methylphenidate treatment in epilepsy patients with comorbid adult attention deficit hyperactivity disorder (ADHD).
Six of 156 consecutive patients attending a tertiary epilepsy clinic for diagnostic evaluation of new seizures, 3 patients with epilepsy and 3 patients with psychogenic non-epileptic seizures, were diagnosed with comorbid adult ADHD. These 6 patients entered an open trial of methylphenidate 10 mg twice daily. Clinical improvement was assessed at 6 weeks of follow-up.
Both groups showed clinical improvement of ADHD symptoms during treatment. None of the patients with comorbid epilepsy experienced adverse effects on seizure control or antiepileptic drug use.
In this open trial methylphenidate was safely used in patients with epilepsy and adult ADHD. It was effective against adult ADHD, and there were no adverse effects on seizure severity and frequency. A randomized study is needed to further establish effectiveness and safety.
本研究旨在评估哌甲酯治疗合并成人注意力缺陷多动障碍（ADHD）的癫痫患者的有效性和安全性。
在一家三级癫痫诊所连续就诊以对新发癫痫进行诊断评估的156例患者中，6例被诊断为合并成人ADHD，其中3例为癫痫患者，3例为精神性非癫痫发作患者。这6例患者进入一项开放试验，服用哌甲酯，每日两次，每次10毫克。在随访6周时评估临床改善情况。
两组在治疗期间ADHD症状均有临床改善。合并癫痫的患者中无一例在癫痫控制或抗癫痫药物使用方面出现不良反应。
在这项开放试验中，哌甲酯在癫痫合并成人ADHD患者中使用安全。它对成人ADHD有效，且对癫痫严重程度和发作频率无不良影响。需要进行一项随机研究以进一步确定其有效性和安全性。
Zotero 插件